<?xml version="1.0" encoding="UTF-8"?>
<p id="p0015">Enzyme replacement therapy with recombinant human IDS (idursulfase, Elaprase, and idursulfase beta, Hunterase) has been used to treat MPS II and is known to improve the aforementioned somatic symptoms.
 <xref rid="bib5" ref-type="bibr">5</xref>, 
 <xref rid="bib6" ref-type="bibr">6</xref>, 
 <xref rid="bib7" ref-type="bibr">7</xref>, 
 <xref rid="bib8" ref-type="bibr">8</xref> However, intravenously administrated idursulfase cannot cross the blood-brain barrier (BBB) in sufficient quantity to address the neurocognitive disorders caused by MPS II, which remain a debilitating issue for patients and are therefore a major focus of lysosomal disorder research.
 <xref rid="bib3" ref-type="bibr">
  <sup>3</sup>
 </xref>
</p>
